New Study: Evaluating Depression and Anxiety in Thai Adolescents with HIV

Dr. Tavitiya Sudjaritruk, Research Institute for Health Sciences, Chiang Mai University
Dr. Tavitiya Sudjaritruk, Research Institute for Health Sciences, Chiang Mai University

U.S. studies have estimated that as many as 60% of HIV-infected adolescents suffer from depression, anxiety, or attention deficit hyperactivity disorder, and it is widely thought that these conditions contribute to the high rates of poor adherence and treatment failure seen in this population. As part of TREAT Asia’s initiative to address the mental health concerns of adolescents living with HIV in Asia, a new study funded through the US National Institutes of Health IeDEA collaboration is evaluating the prevalence and clinical course of depression and anxiety in Thai adolescents with HIV.

Read more


AREF Excell Researcher and Leadership
Development Programme

The Africa Research Excellence Fund (AREF) is delighted to announce the launch of the Excell Researcher and Leadership Development Programme funded with a grant from the Robert Bosch Stiftung

Application deadline: 15th March 2018

The aim of the Excell programme is to enhance research capacity in global health – by African scientists in Africa for Africa. Through this 2-year programme, AREF will work closely with four to six research institutions from Sub-Saharan Africa, selected competitively. AREF will enable 20 individual researchers (nominees) from our participating research institutions to realise their potential – build strong research careers, empower excellent teams, win funding and collaborate internationally.

In the 18 months from May 2018 to October 2019, the programme will include: Continue reading “AREF Excell Researcher and Leadership
Development Programme”

Mark Wainberg Fellowship Programme: Experts in HIV service delivery – Call for applications

Application deadline 19 February 2018

The Mark Wainberg Fellowship Programme, an initiative of the IAS Educational Fund,  is aimed at contributing to improving the quality of HIV service delivery in resource-limited settings by providing two-year fellowships to five clinicians from sub-Saharan Africa, who will spend one year in Europe and one year in Africa at clinical institutions. The programme will offer in-depth training for clinicians committed to careers in HIV clinical service delivery in sub-Saharan Africa with the aim of strengthening access to high-quality services for sub-Saharan Africa populations, with a client-centred service delivery approach.

read more

12th INTEREST Conference

29 May – 1 June 2018, Kigali, Rwanda

The 12th INTEREST Conference (known as the ‘African CROI’) will take place from 29 May – 1 June 2018 in Kigali, Rwanda.  The Conference brings together scientists involved in HIV treatment, pathogenesis, and prevention research in Africa to share pivotal findings, promote collaboration, and transfer experiences across several fields and many continents. The conference will showcase cutting-edge knowledge in the diagnosis and treatment of HIV and the prevention of the HIV-1 infection. Additionally, it will continue to foster building a community of African physicians and scientists to facilitate the implementation of local solutions for the management of patients living with HIV-1 infection and for the prevention of HIV transmission.  Continue reading “12th INTEREST Conference”

AIDS 2018 – 22nd International AIDS Conference

The International AIDS Conference is the largest conference on any global health or development issue in the world. First convened during the peak of the epidemic in 1985, it continues to provide a unique forum for the intersection of science, advocacy, and human rights – leaving behind lasting legacies in each host country.

The 22nd International AIDS Conference (AIDS 2018) will be hosted in Amsterdam, Netherlands on 23-27 July in 2018 under the theme – ‘Breaking Barriers, Building Bridges.’

Registration opens on 1 December 2017

HIV drug resistance now high enough to trigger a change in first-line treatment in eastern and southern Africa

HIV drug resistance is increasing rapidly in southern and eastern Africa and Latin America and, as a result, it may soon be necessary to change the recommended first-line antiretroviral drug regimen in many countries to integrase inhibitor-based treatment, according to an analysis published in The Lancet Infectious Diseases on 30 November.